Drug could slash surgeries for rare airway disease
NCT ID NCT05797246
First seen Jun 26, 2026 · Last updated Jul 31, 2026 · Updated 4 times
Summary
This phase II trial tests whether bevacizumab, a drug that blocks blood vessel growth, can lengthen the time between surgeries for adults with recurrent respiratory papillomatosis (RRP), a rare condition causing wart-like growths in the airways. Participants receive 11 doses of the drug over about a year after surgery to remove growths. The goal is to see if the treatment reduces how often surgery is needed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- bevacizumab
- What this could lead to
- If it works, this could mean fewer surgeries for people with RRP, helping them breathe and speak more easily.
- What could go wrong
- This is a small, early-phase trial with only 21 participants, so results may not apply to everyone. Bevacizumab can cause side effects like high blood pressure or bleeding.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DISEASE ATTRIBUTES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple screening program could transform cancer aftercare
- Can lifestyle choices after a stroke extend life and prevent a second one?
- A new program aims to ease the 'Lost in Transition' struggle for cancer survivors
- Strumming for the brain: could ukulele lessons sharpen minds in MS?
- A gentle touch against coughs and colds: could manual therapy shorten respiratory illness?
- Can a new immune drug outsmart Hard-to-Treat tumors?